全球生物製劑市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計生物製藥市場將從 2025 年的 6,402 億美元成長到 2034 年的 15,673.4 億美元，2026 年至 2034 年的複合年成長率為 10.46%。

全球生物製藥市場正經歷顯著成長，主要受對治療慢性複雜疾病的先進治療方法需求不斷成長的推動。單株抗體、疫苗和重組蛋白等生物製藥已徹底改變了腫瘤、自體免疫疾病和感染疾病的治療方法。文明病的日益增加和醫療保健支出的不斷成長也促進了市場的強勁成長。

生物技術的進步和生產過程的改進是成長要素。生物相似藥的普及也提高了多個地區的市場可近性和可負擔性。研發投入的增加，以及強大的臨床管線，進一步加速了全球生物製藥研發的創新。

隨著包括基因療法和細胞療法在內的新一代生物製劑日益受到關注，其未來前景十分光明。新興國家醫療基礎設施的擴建將開闢新的成長途徑。大規模生產和低溫運輸物流技術的進步可望提高分銷效率。對個人化醫療的持續關注將進一步鞏固生物製劑在製藥業的重要地位。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球生物製劑市場：依來源分類

• 市場分析、洞察與預測
• 微生物來源
• 哺乳動物起源
• 其他

第5章 全球生物製劑市場：依產品分類

• 市場分析、洞察與預測
• 單株抗體
• 疫苗
• 重組蛋白
• 反義和RNAi療法
• 其他

第6章 全球生物製劑市場：依疾病類別分類

• 市場分析、洞察與預測
• 腫瘤學
• 感染疾病
• 免疫系統疾病
• 心血管疾病
• 血液疾病
• 其他

第7章 全球生物製劑市場：依製造商分類

• 市場分析、洞察與預測
• 外包
• 內部生產

第8章 全球生物製劑市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Samsung Biologics
  • Amgen Inc
  • Novo Nordisk A/S
  • AbbVie Inc
  • Sanofi
  • Johnson & Johnson Services Inc
  • Celltrion Healthcare Co. Ltd
  • Bristol-Myers Squibb Company
  • Eli Lilly And Company
  • F. Hoffmann La-Roche Ltd

The Biologics Market size is expected to reach USD 1567.34 Billion in 2034 from USD 640.20 Billion (2025) growing at a CAGR of 10.46% during 2026-2034.

The Global Biologics Market is growing significantly due to rising demand for advanced therapies to treat chronic and complex diseases. Biologics, including monoclonal antibodies, vaccines, and recombinant proteins, have transformed treatment approaches in oncology, autoimmune disorders, and infectious diseases. Increasing prevalence of lifestyle-related illnesses and higher healthcare expenditure are contributing to strong market expansion.

Primary growth drivers include advancements in biotechnology and improved manufacturing processes. The expansion of biosimilars has also enhanced market accessibility and affordability in several regions. Growing investments in research and development, along with strong clinical pipelines, are further supporting innovation in biologic drug development globally.

Future prospects remain highly promising as next-generation biologics, including gene and cell therapies, gain traction. Expanding healthcare infrastructure in emerging economies will open new growth avenues. Technological improvements in large-scale production and cold chain logistics are expected to enhance distribution efficiency. The continued focus on personalized medicine will further solidify biologics as a dominant segment in the pharmaceutical industry.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Source

• Microbial
• Mammalian
• Others

By Product

• Monoclonal Antibodies
• Vaccines
• Recombinant Proteins
• Antisense & RNAi Therapeutics
• Others

By Disease Category

• Oncology
• Infectious Diseases
• Immunological Disorders
• Cardiovascular Disorders
• Hematological Disorders
• Others

By Manufacturing

• Outsourced
• In-House

COMPANIES PROFILED

• Samsung Biologics, Amgen Inc, Novo Nordisk AS, AbbVie Inc, Sanofi, Johnson Johnson Services Inc, Celltrion Healthcare Co Ltd, BristolMyers Squibb Company, Eli Lilly and Company, F Hoffmann LaRoche Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOLOGICS MARKET: BY SOURCE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Source
• 4.2. Microbial Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Mammalian Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOLOGICS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product
• 5.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Recombinant Proteins Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Antisense & RNAi Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOLOGICS MARKET: BY DISEASE CATEGORY 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Disease Category
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Immunological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Cardiovascular Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Hematological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BIOLOGICS MARKET: BY MANUFACTURING 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Manufacturing
• 7.2. Outsourced Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. In-House Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BIOLOGICS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Source
  • 8.2.2 By Product
  • 8.2.3 By Disease Category
  • 8.2.4 By Manufacturing
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Source
  • 8.3.2 By Product
  • 8.3.3 By Disease Category
  • 8.3.4 By Manufacturing
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Source
  • 8.4.2 By Product
  • 8.4.3 By Disease Category
  • 8.4.4 By Manufacturing
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Source
  • 8.5.2 By Product
  • 8.5.3 By Disease Category
  • 8.5.4 By Manufacturing
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Source
  • 8.6.2 By Product
  • 8.6.3 By Disease Category
  • 8.6.4 By Manufacturing
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BIOLOGICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Samsung Biologics
  • 10.2.2 Amgen Inc
  • 10.2.3 Novo Nordisk A/S
  • 10.2.4 AbbVie Inc
  • 10.2.5 Sanofi
  • 10.2.6 Johnson & Johnson Services Inc
  • 10.2.7 Celltrion Healthcare Co. Ltd
  • 10.2.8 Bristol-Myers Squibb Company
  • 10.2.9 Eli Lilly And Company
  • 10.2.10 F. Hoffmann La-Roche Ltd